<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341363</url>
  </required_header>
  <id_info>
    <org_study_id>2000027404</org_study_id>
    <nct_id>NCT04341363</nct_id>
  </id_info>
  <brief_title>Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling</brief_title>
  <official_title>Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this study is to evaluate the efficacy of microneedling through use of a
      professional tattoo machine in hair regrowth in patients with androgenic alopecia (AGA) over
      up to 6 treatments (6 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proposed is an open label trial of tattoo machine microneedling in ten patients with
      androgenic alopecia. Ten healthy male patients older than 18 years will undergo 6
      microneedling sessions. Over the course of six months, subjects will undergo up to six
      treatment sessions (one session every 30 day). Patients will be evaluated at 8 visits over 8
      months with the first visit for screening purposes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total area hair count</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of hairs in an area of 1 cm^2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton-Norwood score</measure>
    <time_frame>6 months</time_frame>
    <description>Scale to classify male pattern baldness based on pattern of hair loss, ranges from I (mild male pattern baldness) to VII (severe male patterned baldness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hair shaft diameter</measure>
    <time_frame>6 months</time_frame>
    <description>The diameter of the hair shaft as measured by trichoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in follicular units</measure>
    <time_frame>6 months</time_frame>
    <description>Number of follicular units with one or more hair follicles over an area of 1cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of yellow dots</measure>
    <time_frame>6 months</time_frame>
    <description>Number of yellow dots over an area of 1cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of white dots</measure>
    <time_frame>6 months</time_frame>
    <description>Number of white dots over an area of 1cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perifollicular halo</measure>
    <time_frame>6 months</time_frame>
    <description>Presence and number of perifollicular halos over an area of 1cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hair phase</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of anagen hairs, catagen hairs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vellus hairs</measure>
    <time_frame>6 months</time_frame>
    <description>Number of vellus hairs over an area of 1 cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal hairs</measure>
    <time_frame>6 months</time_frame>
    <description>Terminal hairs over an area of 1 cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hair phase</measure>
    <time_frame>6 months</time_frame>
    <description>Number of anagen, catagen hairs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Androgenic Alopecia</condition>
  <arm_group>
    <arm_group_label>Microneedling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with androgenic alopecia will receive microneedling with a tattoo machine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tattoo machine</intervention_name>
    <description>A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.</description>
    <arm_group_label>Microneedling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symmetric hair loss from AGA

          -  Hamilton-Norwood IIIa, III, III vertex, IV, Iva, V with low density hair coverage over
             majority of alopecic areas

          -  No or minimal scalp hair regrowth on oral and/or topical minoxidil

        Exclusion Criteria:

          -  Any male with hair loss for other reasons

          -  Unilateral or asymmetric hair loss

          -  Hamilton-Norwood I, II, IIa, Va, IV, VII x

          -  Patients without hair

          -  Patients with the following who would make poor candidates for microneedling such as
             skin conditions, diabetes, or history of keloid formation

          -  Anything additional existing comorbidities that in the opinion of the investigator may
             cause unnecessary risk for the patient to participate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study investigator</last_name>
    <phone>(203) 785-3482</phone>
    <email>danielle.peterson@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brett King, MD, PhD</last_name>
    <email>Brett.King@yale.edu</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

